Loading
Thousands of cancer compounds that stopped development for portfolio rather than scientific reasons sit unused in university freezers and company archives. A public catalogue listing each asset's mechanism, stage, data, reason for stopping and licensing contact, with a standard research licence and a brokerage function, would let academic and non-profit developers adopt them.
A searchable registry where universities and companies list oncology assets that have stopped development (with mechanism, stage reached, available data, reason for stopping and licensing contact), coupled with a standard non-exclusive research licence and a small brokerage function to match assets with academic groups or non-profit developers. NCATS's discontinued assets programme and AstraZeneca's open innovation portal are partial precedents; the National Cancer Institute's NExT programme has taken up some shelved compounds. Most stopped programmes end for portfolio, not scientific, reasons, and their data are otherwise lost.
Shares Automatic offer of shelved cancer assets to non-profits after two years, A non-profit pharmaceutical company for the cancers markets ignore.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares Secrecy and intellectual property block collaboration, Failures are hidden.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
Shares Automatic offer of shelved cancer assets to non-profits after two years, Secrecy and intellectual property block collaboration.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, The valley of death between lab and product.